Novartis AG (NVS)
NYSE: NVS
· Real-Time Price · USD
124.00
1.91 (1.56%)
At close: Aug 15, 2025, 3:10 PM
Novartis Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | 4.02B | 3.61B | 2.82B | 3.19B | 3.25B | 2.69B | 2.64B | 1.51B | 2.32B | 2.29B | 1.47B | 1.57B | 1.7B | 2.22B | 16.31B | 2.76B | 2.9B | 2.06B |
Depreciation & Amortization | 1.26B | 1.15B | 1.63B | 1.97B | 1.16B | 1.31B | 1.59B | 3.11B | 1.82B | 2B | 1.95B | 2.03B | 1.8B | 1.41B | 1.52B | 1.45B | 1.44B | 1.7B |
Stock-Based Compensation | 267M | 262M | 272M | 255M | 257M | 260M | 248M | 205M | 222M | 190M | 197M | 219M | 204M | 203M | 195M | 173M | 185M | 183M |
Other Working Capital | 796M | -608M | -543M | 515M | 611M | -875M | -741M | 1.51B | 512M | -121M | -51M | 920M | -94M | -2.01B | 1.18B | 409M | 130M | -1.47B |
Other Non-Cash Items | 168M | -403M | -995M | -147M | 3.5B | 4.68B | -1.28B | -668M | -1.09B | -474M | -360M | 80M | -239M | -617M | -15.96B | -340M | -1.13B | -726M |
Deferred Income Tax | 507M | 798M | 465M | 200M | 595M | 441M | -261M | 39M | 452M | 446M | 275M | 344M | 347M | 450M | 645M | 472M | 611M | 391M |
Change in Working Capital | 442M | -1.77B | 5M | 824M | -50M | -2.33B | -384M | 1.18B | -162M | -1.5B | 585M | 477M | -54M | -2.01B | 1.18B | 409M | 130M | -1.47B |
Operating Cash Flow | 6.66B | 3.65B | 4.19B | 6.29B | 4.88B | 2.27B | 2.55B | 5.38B | 3.58B | 2.96B | 4.11B | 4.72B | 3.75B | 1.65B | 3.88B | 4.92B | 4.13B | 2.13B |
Capital Expenditures | -558M | -1.49B | -1.13B | -799M | -728M | -1.16B | -783M | -683M | -996M | -470M | -647M | -582M | -583M | -859M | -977M | -539M | -597M | -858M |
Cash Acquisitions | -1.68B | 6M | -264M | -50M | -3.28B | -278M | -11M | -3.45B | -86M | -42M | -11M | 8M | -61M | -839M | 20.33B | -17M | -2M | -211M |
Purchase of Investments | -58M | -55M | -2.31B | -1.01B | -282M | -50M | -573M | -39M | -31M | -107M | -10.58B | -6.71B | -13.27B | -4.26B | -15.63B | -807M | -87M | -86M |
Sales Maturities Of Investments | 50M | 1.88B | 581M | 1.47B | 1.06B | 585M | 179M | 290M | 50M | 11.08B | 9.66B | 12.46B | 2.15B | 15.22B | 689M | 22M | 246M | 1.8B |
Other Investing Acitivies | -226M | -1.24B | -487M | -466M | 20M | -431M | -572M | 1.67B | 10M | 162M | 108M | 21M | 140M | 99M | 153M | 109M | 537M | 132M |
Investing Cash Flow | -2.24B | 330M | -3.03B | -374M | -3.21B | -899M | -1.76B | -2.21B | -1.05B | 10.62B | -1.47B | 5.2B | -11.63B | 9.37B | 4.56B | -1.23B | 97M | 780M |
Debt Repayment | 181M | -523M | -106M | 2.51B | 833M | 1.15B | 610M | -2.29B | -709M | 933M | -1.2B | -1.95B | n/a | 404M | -3.11B | -78M | -2.37B | 755M |
Common Stock Repurchased | -2.71B | -2.72B | -2.76B | -2.85B | -1.62B | -1.1B | -1.25B | -1.63B | -2.96B | -2.89B | -2.68B | -2.72B | -2.71B | -2.54B | -148M | -284M | -703M | -1.92B |
Dividend Paid | -2.48B | -5.33B | n/a | n/a | -2.42B | -5.21B | n/a | n/a | n/a | -7.25B | n/a | n/a | n/a | -7.51B | n/a | n/a | n/a | -7.37B |
Other Financial Acitivies | -195M | 24M | -128M | -38M | n/a | -11M | 34M | 3.08B | 29M | 6M | -116M | -70M | 412M | 116M | 7M | -1.17B | 135M | -5M |
Financial Cash Flow | -5.21B | -8.55B | -3B | -382M | -3.2B | -5.16B | -607M | -832M | -3.64B | -9.2B | -3.99B | -4.74B | -2.3B | -9.53B | -3.25B | -1.53B | -2.94B | -8.54B |
Net Cash Flow | -410M | -4.39B | -2.15B | 5.71B | -1.57B | -3.92B | 988M | 1.52B | -1.11B | 4.48B | -1.21B | 5.1B | -10.23B | 1.45B | 5.2B | 2.09B | 1.32B | -5.86B |
Free Cash Flow | 6.11B | 2.15B | 3.06B | 5.49B | 4.15B | 1.11B | 1.76B | 4.7B | 2.58B | 2.49B | 3.46B | 4.14B | 3.17B | 790M | 2.91B | 4.39B | 3.54B | 1.27B |